User:Sutefu/sandbox

AllTrials (sometimes called All Trials or AllTrials.net) is a collaborative project which advocates that clinical research adopt principles of open research. The project summarizes itself as "All trials registered, all results reported": that is, all clinical trials should be listed in a clinical trials registry, and their results should always be shared as open data.

At the center of the campaign is a petition signed by over 85,000 individuals and 599 organisations (as of August 2015):

Ben Goldacre, author of Bad Science and Bad Pharma, is a founder of the campaign and its most public spokesperson.

History
The AllTrials campaign was launched by the British charity Sense About Science on in January 2013. AllTrials was born from dissatisfied participants of clinical trials, who felt that their contributions to clinical research was lost because pharmaceutical companies neglected to publish results of said clinical trials. The campaign came to life with a letter written by 53 clinical trials participants, which was directly addressed to the executive director of the European Medical Agency on January 18th 2013. This letter clearly stated their dissatisfaction with the fact that the results of half of clinical trials do not get published or reported. The campaign subsequently quickly gained traction and reached a major turning point by gaining the support from one of the biggest pharmaceutical companies, GlaxoSmithKline, in 2013. In the same year, the campaign recruited its supporters to assist in the redrafting of the European clinical trials law to erase legal loopholes and increase a legal obligation for the reporting of clinical trial data. They were joined in this endeavour by European MP Glenis Willmott. The new Clinical Trials Regulation law was passed in April 2014. In 2015, the World Health Organization published their position on the reporting of clinical trials, which aligns with the goals of the AllTrials campaign, thus increasing pressure on regulating bodies to require the publication of clinical trial results.

Mission
The project is a reaction to under-reporting of research.

A substantial proportion (estimates range from one-third to one-half) of medical research goes unpublished. It has also been shown that negative findings are less likely to be published than positive ones, even in the absence of conflicts of interest.

Much medical research is done by the pharmaceutical industry, which have a conflict of interest reporting results which may hurt sales of their products. There is a measurable bias in reporting; studies have shown that published drug studies funded by pharmaceutical companies are much more likely to support the use of the tested drug than studies with other funding. Industry-funded trials are also less likely to be published

If the statistical methods used to analyse the trial are not chosen before the study it started, there is a danger that researchers will intentionally or unintentionally pick the method that gives the results they expect, or which gives the most significant results. This makes the analysis statistically invalid.

Pre-trial registration makes non-publication and changes in analysis methods obvious to medical reviewers. It also enables authors of meta-studies to track down and analyse missing data.

There are other sources of bias, such as the conditions sometimes attached to funding by funding agencies with a financial interest in the trial's outcome. Medical researchers may be asked to agree to allow the funding agency to censor results. Some funding agencies may also refuse to give the medical researcher access to the raw data, giving them only the finished analysis, or even a draft paper, and asking them to put their name to it. This is not acceptable academic practice, and some academic journals require that authors sign a statement that they have not entered into such agreements.

Ben Goldacre, a physician and spokesperson for the campaign, would like to address the systematic flaws in clinical research which cause data to be lost after it is gathered.

Coverage
The campaign has been widely covered, and supported, in the academic press. The British Medical Journal and PLOS are founding members. Nature and The Lancet both published supportive articles in January 2014.

There has also been mainstream media coverage.

Criticism
There has been criticism from the Pharmaceutical Research and Manufacturers of America (PhRMA), with senior vice-president Matt Bennett saying that trial data disclosure measures which AllTrials has recommended to the European Medicines Agency "could risk patient privacy, lead to fewer clinical trials, and result in fewer new medicines to meet patient needs and improve health.".

AllTrials have published a detailed statement of exactly what they want to see published, which states "The AllTrials campaign is not calling for individual patient data to be made publicly available" [bolding original].

A 2012 editorial published by senior regulators from the European Medicines agency largely agreed with AllTrials, saying "We consider it neither desirable nor realistic to maintain the status quo of limited availability of regulatory trials data". They were also of the opinion that adequate standards for protection of personal data could be written. However, they warned that third party reanalysis was neither a guarantee of quality nor of lack of conflict of interest, which, in the worst case, could lead to negative public health consequences.

They suggested that reanalyses should therefore be subject to the same regulations as sponsor analyses, such as registering analysis plans. They argued against completely unrestricted access to data, but in favour of broader access. AllTrials is not calling for completely unrestricted access to raw data, so the scope of disagreements is limited to what restrictions should be in place.

Supporters
The campaign is an initiative of the charity Sense About Science, Bad Science , BMJ, the James Lind Initiative and the Centre for Evidence-Based Medicine. In April 2013, The Cochrane Collaboration joined these organizations as a core contributor to the campaign. In the same year, the European Consumer Organisation,

The campaign is an initiative of Sense About Science, Centre for Evidence Based Medicine, The Dartmouth Institute for Health Policy and Clinical Practice, James Lind Alliance, Cochrane Collaboration, BMJ Group, PLOS, and Bad Science. The petition statement of AllTrials has been signed by organizations including Wellcome Trust, British Library, Medical Research Council (UK), British Heart Foundation, Institute for Quality and Efficiency in Health Care, National Institute for Health and Care Excellence, BioMed Central, National Physicians Alliance, Royal Society of Medicine, Health Research Authority, American Medical Student Association, GlaxoSmithKline, and others.

In August 2013 there were 55,000 signatories supporting the campaign. In August 2015 there were over 85,000 signatories supporting the campaign.

85 investors with >€3.5 trillion (£2.45trn; $3.83trn) of investments have supported AllTrials (as of July 2015), with Peter van der Werf of RobecoSAM saying: "We deem this to be a financially material factor and encourage all companies to gain credibility regarding their approach to clinical trial transparency by signing up to the AllTrials principles.".

Opponents
The European Federation of Pharmaceutical Industries and Associations and Pharmaceutical Research and Manufacturers of America have expressed interest in lobbying against the campaign. Campaign supporters criticized Hoffmann-La Roche's plans to be more open but not to the extent requested by AllTrials.